Good MorningEquity markets advanced on Tuesday in hopes that stability in the trade outlook would soon emerge. With maximum uncertainty in the air, simply solidifying the outlook regardless of tariffs could be enough to catalyze a significant broad market stock rally. The index is in rebound mode and moving higher, with eyes on the 5,700 level. Moving above it would trigger the market, leading to a retest of the all-time high.
Economic data and earnings are other potential catalysts for stocks this week. The monthly labor data is due, and the first report, the JOLTs report, was weaker than expected but still shows ample job availability. Regarding earnings, reports from Microsoft, Meta Platforms, and Amazon will give a deep look into the state of tech spending, and it is expected to be strong. The question is whether they will outperform consensus estimates and provide positive guidance, and the odds are high they will due to the low bar set by analysts. Featured: 5 dividend stocks worth owning in any market condition (Ad) 
|
Technology | |
It's said about the weather that if you give it a few minutes it will change. The same could be true about sentiment for CrowdStrike Holdings Inc. (NASDAQ: CRWD). The company is a month away from earnings, and the stock is behaving in a volatile fashion. At the beginning of April, CRWD stock was... Read the Full Story |
|
From Our Partners | | Renewed tensions involving Iran are putting global oil supplies back in focus - and history shows certain energy stocks respond before the broader market catches on.
A new report identifies three energy stocks emerging from today's supply disruptions. One is already benefiting from the current environment; the other two may not be on your radar yet. | | See which three energy stocks made the list and why they stand out |
|
Consumer Staples | |
Tariff-resistant Altria Group (NYSE: MO) is still a good buy in 2025 because its business profitability is improving despite declining sales. The decline in sales is primarily due to reduced use of smokeable products, offset by increasing use of consumable and smokeless products.
The critical de... Read the Full Story |
|
Transportation | |
A late April 2025 rally in the S&P 500 has sparked a wave of investor optimism, with some asserting that the market has fully absorbed the effects of President Trump’s tariffs. However, this optimism may be premature.
Key indicators point to significant headwinds ahead. Entrenched inf... Read the Full Story |
|
From Our Partners | | Most AI portfolios hold the same handful of chip and software names - and completely ignore the physical layer. One perception-hardware company posted ~49% Q1 revenue growth with four partnership announcements in a single month.
A free report names seven companies building the automation, robotics, and semiconductor-test infrastructure that AI requires to move beyond the data center - including an automation giant that raised full-year guidance after quarterly sales rose ~12%. | | Click here to get your free copy of this report today |
|
Consumer Staples | |
Coca-Cola’s (NYSE: KO) stock price can bubble to new highs this year because its Q1 results and guidance update show its everywhere-is-local approach to business and international growth agenda is working.
The company faces headwinds in 2025 like virtually every other S&P 500 business... Read the Full Story |
|
Consumer Staples | |
With tariffs causing markets to waver in 2025, many investors were growing worried about the guidance companies would put out. Analysts expect certain stocks not to give guidance for the rest of the year due to the difficulty in forecasting amid the tariff policy environment.
Additionally, many s... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Retail/Wholesale | |
Domino’s Pizza (NASDAQ: DPZ) faces challenges and headwinds in 2025, but its results and guidance show that it can build leverage despite these obstacles. The Q1 results include system-wide growth and improved profitability, attributed to the Hungry for MORE strategy.
Guidance was reaffir... Read the Full Story |
|
Technology | |
Intel (NASDAQ: INTC) reported seemingly positive first-quarter financial results, exceeding expectations for adjusted earnings per share (EPS) and revenue.
However, this initial positive sentiment quickly faded due to the company's very cautious outlook for the second quarter, forecasting break... Read the Full Story |
|
Technology | |
The technology sector, which had been primarily responsible for powering the market’s recent ascent until this year, was at the forefront of the recent downturn, weighed down by global economic uncertainty and a renewed wave of risk-off sentiment. However, within the broader tech landscape, ... Read the Full Story |
|
Technology | |
As a disruptor in the computer and technology sector, specifically the telecommunications industry, T-Mobile US (NASDAQ: TMUS) proudly calls itself the "Un-carrier." This originated in March 2013, when they set out to differentiate themselves against the incumbent telecom “carriers” ... Read the Full Story |
|
Multi-Sector Conglomerates | |
From Scotch tape and Ace bandages to Filtrete air filters and Post-It Notes, 3M Co. (NYSE: MMM) products are often taken for granted in everyday life. Yet, when consumers run out of them, that’s when their true value is revealed. The same applies to its stock. The multi-sector conglomerate... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
